Drugξ | Indication | Date Results Announced | Date Funded¥ | Elapsed Number of Months€ | Episodes of Media Coverage | Number Media Reports Per Month |
---|---|---|---|---|---|---|
Liposomal doxorubicin [14] | Relapsed ovarian | 21-05-00 | 01-10-01 | 16 | 0 | 0 |
Imatinib (PO) [15] | Unresectable GIST | 18-05-01 | 20-02-03 | 22 | 2 | 0.09 |
Zoledronic acid [16] | Metastatic prostate | 02-06-01 | 01-01-04 | 31 | 1 | 0.03 |
Zoledronic acid [17] | Metastatic breast | 21-10-01 | Ongoing | 46 | 1 | 0.02 |
Docetaxel [18] | Neoadjuvant breast | 10-12-01 | 01-08-04 | 32 | 3 | 0.09 |
Anastrazole (PO) [19] | Adjuvant breast | 10-12-01 | 22-02-05 | 39 | 33 | 0.85 |
Docetaxel [20] | 1st line ovarian | 18-05-02 | Ongoing | 38 | 1 | 0.03 |
Liposomal doxorubicin [21] | Metastatic breast | 18-05-02 | Ongoing | 38 | 1 | 0.03 |
TAC [22] | Adjuvant breast | 19-05-02 | Ongoing | 38 | 6 | 0.16 |
Premetrexed [23] | Mesothelioma | 20-05-02 | Ongoing | 38 | 7 | 0.18 |
Vinorelbine/trastuzumab [24] | Metastatic breast | 12-12-02 | 01-08-05 | 32 | 0 | 0 |
Letrozole (PO) [25] | Adjuvant breast | 05-12-03 | Ongoing | 20 | 16 | 0.8 |
Capecitabine (PO) [26] | Adjuvant colon | 06-06-04 | Ongoing | 16 | 0 | 0 |
Vinorelbine [27] | Adjuvant NSCLC | 06-06-04 | 01-08-05 | 14 | 17 | 1.21 |
Paclitaxel [28] | Adjuvant NSCLC | 06-06-04 | Ongoing | 14 | 3 | 0.21 |
Bortezomib [29] | Relapsed myeloma | 06-06-04 | Ongoing | 14 | 13 | 0.93 |
Docetaxel [30] | Metastatic prostate | 07-06-04 | 01-08-05 | 14 | 17 | 1.21 |
Trastuzumab [12–13] | Adjuvant breast | 16-05-05 | 01-08-05 | 3 | 51 | 17 |